Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...
In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the ...
Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
New insights into a sophisticated process that protects sperm cells has revealed a mechanism, similar to an immune system, ...
This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.
For decades, aging has looked like a one-way street, a slow accumulation of damage written into our cells. Now a wave of ...
New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...
CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved for the treatment of patients with multiple myeloma who have had at least one prior line of therapy. Globally, CARVYKTI ® is ...
Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have found that a key ...